NASDAQ, ATHX - Athersys Inc
We are a biopharmaceutical company engaged in the discovery and development of
therapeutic product candidates designed to extend and enhance the quality of
human life. Through the application of our proprietary technologies, we have
established a pipeline of therapeutic product development programs in multiple
diseases. In 2007, we advanced our lead program for treating obesity into
clinical development. We also advanced two additional programs in 2007,
receiving authorization for Investigational New Drug applications, or INDs, for
treatment of acute myocardial infarction, or AMI, and the complications (e.g.,
graft versus host disease) associated with hematopoietic stem cell/bone marrow
transplantation for certain hematologic malignancies. We have additional
programs in discovery and preclinical development for the treatment of ischemic
stroke and certain cognitive or attention disorders. ...
Read SEC Filing on NASDAQ.com »